KSCM
ABBV icon

Kamunting Street Capital Management’s AbbVie ABBV Stock Holding History

Kamunting Street Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,450
Closed -$2.35M – 28
2023
Q2 		$2.35M Buy
+17,450
New +$2.56M 2.33% 10

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kamunting Street Capital Management's ABBV Position: Q3 2023 in Review

Kamunting Street Capital Management sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 17,450 shares — an estimated $2.35M sold.

Kamunting Street Capital Management first reported a position in ABBV in Q2 2023 and held it in 1 quarter. The position peaked at $2.35M in Q2 2023. 3,109 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Kamunting Street Capital Management reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
  • Kamunting Street Capital Management sold 17,450 AbbVie shares in Q3 2023, an estimated $2.35M.
  • Kamunting Street Capital Management first reported a position in AbbVie in Q2 2023 and held it in 1 quarter.
  • Kamunting Street Capital Management's AbbVie position peaked at $2.35M in Q2 2023.
  • 3,109 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Kamunting Street Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.